Volume 28, Issue 1 (1-2024)                   IBJ 2024, 28(1): 1-7 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sadat Larijani M, Biglari A, Sorouri R, Salehi-Vaziri M, Doroud D, Azadmanesh K, et al . Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran. IBJ 2024; 28 (1) :1-7
URL: http://ibj.pasteur.ac.ir/article-1-3964-en.html
The present study aims to provide an insight to the comprehensive efforts of Pasteur Institute of Iran (PII) regarding COVID-19 management, research, achievements, and vaccine production, though there are many challenges. The relevant literature review was investigated through national and international database and also reports from the related research departments. Six strategies were taken by PII to manage the pandemic of COVID-19. While this pandemic has been hopefully controlled, SARS-CoV-2 could still be a potential threat. Therefore, COVID-19 data management and updated studies, as well as long-term safety and efficacy of the SARS-CoV-2 vaccines are still on the agenda.
Type of Study: Perspective Review | Subject: Related Fields

1. Maslehat S, Mostafavi E. The role of Pasteur Institute of Iran in disinfection of drinking water of Tehran (1950-1954). J Res Hist Med. 2018;7(2):117-26.
2. Enayatrad M, Mostafavi E. Pasteur Institute of Iran: History and services. J Res Hist Med. 2017; 6(4): November 2017.
3. Keypour M, Yousefi Behzadi M, Mostafavi E. Remembering Marcel Baltazard, great researcher and the French president of Pasteur Institute of Iran. Arch Iran Med. 2017; 20(8):553-7.
4. Dejman M, Habibi E, Baradarn Eftekhari M, Falahat K, Malekafzali H. Pasteur Institute of Iran-an evaluation model. Iran Biomed J. 2014; 18(3):189-95.
5. Fayaz A, Fallahian V, Simani S, Eslamifar A, Mohammadian A, Hazrati M, et al. Epidemiological characteristics of persons exposed to rabies in Tehran referred to Pasteur Institute of Iran during the years of 1993-1994 and 2008- 2009. Res Med. 2011; 35(3):168-73.
6. Mostafavi E, Keypour M. History of plague research center of Pasteur Institute of Iran (1952-2016). J Res Hist Med. 2017; 6(3): August 2017.
7. Maslehat S, Doroud D, mostafavi e. Pasteur Institute of Iran; a leading institute in the production and development of vaccines in Iran. Vac Res. 2019; 6(1):33-42. [DOI:10.29252/vacres.6.1.33]
8. Mansoori P, Majdzadeh R, Abdi Z, Rudan I, Chan KY, The Iranian CHNRI Health Research Priority Setting Group, et al. Setting research priorities to achieve long-term health targets in Iran. J Glob Health. 2018; 8(2): 020702. [DOI:10.7189/jogh.08.020702]
9. Mostafavi E, Molaeipoor L, Esmaeili S, Ghasemi A, Kamalizad M, Yousefi Behzadi M, et al. Seroprevalence of Q fever among high-risk occupations in the Ilam province, the west of Iran. PloS one. 2019; 14(2): e0211781. [DOI:10.1371/journal.pone.0211781]
10. Parhizgari N, Gouya MM, Mostafavi E. Emerging and re-emerging infectious diseases in Iran. Iran J Microbiol. 2017; 9(3):122-42.
11. Doosti-Irani A, Mostafavi E, Nazemipour M, Mansournia MA, Haghdoost AA. Challenges for management of the COVID-19 epidemic in Iran. Glob Epidemiol. 2020; 2:100035. [DOI:10.1016/j.gloepi.2020.100035]
12. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. 2020; 382(8):692-4. [DOI:10.1056/NEJMp2000929]
13. Salehi-Vaziri M, Arashkia A, Mostafavi E, Jalali T, Hassan Pouriayevali M, Fazlalipour M, et al. How Iran responded to expanding need for laboratory services for COVID-19? Health Policy Technol. 2021; 10(2):100506. [DOI:10.1016/j.hlpt.2021.100506]
14. Amiri S, Haghdoost A, Mostafavi E, Sharifi H, Peykari N, Raeisi A, et al. Iran COVID-19 epidemiology committee: A review of missions, structures, achievements, and challenges. J Res Health Sci. 2021; 21(1):e00505. [DOI:10.34172/jrhs.2021.45]
15. Moradi G, Mostafavi E, Haghdoost AA. The urgency of conducting serological studies for COVID-19. J Res Health Sci. 2020; 20(2):e00479. [DOI:10.34172/jrhs.2020.14]
16. World Health Organization [Internet]. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance; 2020; Available from: https://www.who.int/publications/i/item/10665-331501.
17. Vogels CB, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol. 2020; 5(10):1299-305. [DOI:10.1038/s41564-020-0761-6]
18. Salehi-Vaziri M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, Pouriayevali MH, Jalali T, et al. The ins and outs of SARS-CoV-2 variants of concern (VOCs). Arch Virol. 2022; 167(2):327-44. [DOI:10.1007/s00705-022-05365-2]
19. Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, et al. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther. 2021; 12(1):410. [DOI:10.1186/s13287-021-02483-7]
20. Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafi-Rasi A, Raoufi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immun Inflamm Dis. 2022; 10(2):201-8. [DOI:10.1002/iid3.563]
21. Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E, et al. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study. Rev Med Virol. 2022; 32(3):e2305. [DOI:10.1002/rmv.2305]
22. Sadat Larijani M, Doroud D, Banifazl M, Karami A, Bavand A, Ashrafian F, et al. A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports. Eur J Med Res. 2023; 28:542. [DOI:10.1186/s40001-023-01531-7]
23. Sadat SM, Aghadadeghi MR, Yousefi M, Khodaei A, Sadat Larijani M, Bahramali G. Bioinformatics analysis of SARS-CoV-2 to approach an effective vaccine candidate against COVID-19. Mol Biotechnol. 2021; 63(5):389-409. [DOI:10.1007/s12033-021-00303-0]
24. Ghafouri F, Cohan RA, Noorbakhsh F, Samimi H, Haghpanah V. An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein. Res. Sq [Priprint]. 2020 May 20. Available from: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7336711/ https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7336711/ [DOI:10.21203/rs.3.rs-30374/v1]
25. Ghafouri F, Ahangari Cohan R, Samimi H, Hosseini Rad SMA, Naderi M, Noorbakhsh F, et al. Development of a multiepitope vaccine against SARS-CoV-2: Immunoinformatics study. JMIR Bioinform Biotech. 2022; 3(1):e36100. [DOI:10.2196/36100]
26. Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali MH, et al. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021; 40(8):1713-9. [DOI:10.1007/s10096-021-04221-6]
27. Larijani SM, Ramezani A, Aghasadeghi MR, Sadat SM. A flash on cell therapy strategies in clinical trials against SARS-CoV-2. Coronaviruses. 2022; 3(2):29-38. [DOI:10.2174/2666796702666210122123559]
28. Beig Parikhani A, Bazaz M, Bamehr H, Fereshteh S, Amiri S, Salehi-Vaziri M, et al. The inclusive review on SARS-CoV-2 biology, epidemiology, diagnosis, and potential management options. Curr Microbiol. 2021; 78(4):1099-114. [DOI:10.1007/s00284-021-02396-x]
29. Sadat Larijani M, Ashrafian F, Bagheri Amiri F, Banifazl M, Bavand A, Karami A, et al. Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran. Microb Pathog. 2022; 169:105618. [DOI:10.1016/j.micpath.2022.105618]
30. Shahbazi B, Mafakher L, Teimoori-Toolabi L. Different compounds against angiotensin-converting enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study. J Mol Model. 2022; 28(4):82. [DOI:10.1007/s00894-022-05059-1]
31. Salehi-Vaziri M, Pouriayevali MH, Fotouhi F, Jalali T, Banifazl M, Farahmand B, et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microb Pathog. 2021; 161:105296. [DOI:10.1016/j.micpath.2021.105296]
32. Sofian M, Velayati AA, Banifazl M, Fotouhi F, Sadat Larijani M, Afzali N, et al. SARS-CoV‑2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms. Wien Med Wochenschr. 2021; 171(1-2):3-6. [DOI:10.1007/s10354-020-00793-8]
33. Adibzadeh S, Amiri S, Nia GE, Taleghani MR, Bijarpas ZK, Maserat N, et al. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Rep. 2022; 27:101619. [DOI:10.1016/j.genrep.2022.101619]
34. Rahimi P, Tarharoudi R, Rahimpour A, Mosayebi Amroabadi J, Ahmadi I, Anvari E, et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J. 2021; 18(1):221. [DOI:10.1186/s12985-021-01692-z]
35. Koushki K, Salemi M, Miri SM, Arjeini Y, Keshavarz M, Ghaemi A. Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19. Biomed Pharmacother. 2021; 144:112346. [DOI:10.1016/j.biopha.2021.112346]
36. Najafi N, Soleimanjahi H, Shahali S, Pourkarim MR, Thijssen M, Fotouhi F, et al. Genomic and serological assessment of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in child labor. Pathog Glob Health. 2022; 116(7):455-61. [DOI:10.1080/20477724.2022.2038052]
37. Toledo-Romani ME, Garcia-Carmenate M, Silva CV, Baldoquin-Rodriguez W, Pérez MM, Rodríguez Gonzalez MC, et al. Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination. medRxiv [Priprint]. 2021. Available from: https://www.medrxiv.org/content/10.1101/2021. 10.31.21265703v2.
38. Gorry C. SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD. MEDICC Rev. 2020; 22(4):10-5. [DOI:10.37757/MR2020.V22.N4.11]
39. Soberana Plus [Internet]. Instituto Finlay de Vacunas Cuba. [cited 2022/04/11]. Available from: https://www.finlay.edu.cu/blog/wp-content/uploads/2021/12/Commercial-file-SOBERANA-Plus-Eng.pdf.
40. Fotouhi F, Salehi-Vaziri M, Farahmand B, Mostafavi E, Pouriayevali MH, Jalali T, et al. Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes Infect. 2021; 23(4-5):104810. [DOI:10.1016/j.micinf.2021.104810]
41. Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. Efficacy and safety of a protein-based SARS-CoV-2 vaccine: a randomized clinical trial. JAMA Netw Open. 2023; 6(5):e2310302.
42. Eybpoosh S, Biglari A, Sorouri R, Ashrafian F, Sadat Larijani M, Verez-Bencomo V, et al. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. PLoS Pathog. 2023; 19(11):e1011744. [DOI:10.1371/journal.ppat.1011744]
43. Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, et al. Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine. Heliyon. 2023; 9(10):e20555. [DOI:10.1016/j.heliyon.2023.e20555]
44. Ramezani A, Sorouri R, Haji Maghsoudi S, Dahmardeh S, Doroud D, Sadat Larijani M, et al. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Sci Rep. 2023; 13(1):8065. [DOI:10.1038/s41598-023-35147-y]
45. Sadat Larijani M, Sorouri R, Eybpoosh S, Doroud D, Moradi L, Ahmadinezhad M, et al. Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study. Pathog Dis. 2023; 81:ftad010. [DOI:10.1093/femspd/ftad010]
46. Ashrafian F, Bagheri Amiri F, Bavand A, Zali M, Sadat Larijani M, Ramezani A. A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between Individuals with comorbidities and the normal population. Vaccines. 2023; 11(8):1376. [DOI:10.3390/vaccines11081376]
47. Hassan PM, Ali T, Saber E, Asghar A, Delaram D, Mostafa SV, et al. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein. Vaccine. 2022; 40(20):2856-68. [DOI:10.1016/j.vaccine.2022.03.066]
48. Islamic Republic News Agancy. Iran, India sign agreement to share knowledge about rotavirus vaccine [Internet]. 2022 [cited 2022 September 13]. Available from: https://en.irna.ir/news/84376732/Iran-India-sign-agreement-to-share-knowledge-about-rotavirus.
49. Simon HU, Karaulov AV, Bachmann MF. strategies to prevent SARS-CoV-2-mediated eosinophilic disease in association with COVID-19 vaccination and infection. Int Arch Allergy Immunol. 2020; 181(8):624-8. [DOI:10.1159/000509368]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb